ALBERT

All Library Books, journals and Electronic Records Telegrafenberg

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Publication Date: 1997-11-14
    Description: The discovery of anticancer drugs is now driven by the numerous molecular alterations identified in tumor cells over the past decade. To exploit these alterations, it is necessary to understand how they define a molecular context that allows increased sensitivity to particular compounds. Traditional genetic approaches together with the new wealth of genomic information for both human and model organisms open up strategies by which drugs can be profiled for their ability to selectively kill cells in a molecular context that matches those found in tumors. Similarly, it may be possible to identify and validate new targets for drugs that would selectively kill tumor cells with a particular molecular context. This article outlines some of the ways that yeast genetics can be used to streamline anticancer drug discovery.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Hartwell, L H -- Szankasi, P -- Roberts, C J -- Murray, A W -- Friend, S H -- N01-BC65017/BC/NCI NIH HHS/ -- New York, N.Y. -- Science. 1997 Nov 7;278(5340):1064-8.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Seattle Project, Molecular Pharmacology Department, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/9353181" target="_blank"〉PubMed〈/a〉
    Keywords: Animals ; *Antineoplastic Agents/pharmacology/therapeutic use ; *Drug Design ; *Drug Screening Assays, Antitumor ; Humans ; Mutation ; Neoplasms/*drug therapy/genetics ; Signal Transduction ; Yeasts/genetics
    Print ISSN: 0036-8075
    Electronic ISSN: 1095-9203
    Topics: Biology , Chemistry and Pharmacology , Computer Science , Medicine , Natural Sciences in General , Physics
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 2
    facet.materialart.
    Unknown
    American Association for the Advancement of Science (AAAS)
    Publication Date: 2006-05-27
    Description: The allure of the emerging genomic technologies in cancer is their ability to generate new biomarkers that predict how individual cancer patients will respond to various treatments. However, productive implementation of cancer biomarkers into patient care will require fundamental changes in how we consider approvals for cancer indications and how we track patient responses. Here we briefly describe ongoing efforts to identify and to validate cancer biomarkers, discuss the technological hurdles that lie ahead, and then focus on the more pressing political and cultural issues that, if left unheeded, could derail many of the anticipated benefits of biomarker research.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Dalton, William S -- Friend, Stephen H -- New York, N.Y. -- Science. 2006 May 26;312(5777):1165-8.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL 33613, USA. dalton@moffitt.usf.edu〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/16728629" target="_blank"〉PubMed〈/a〉
    Keywords: Academies and Institutes ; *Biomarkers, Tumor ; Biotechnology ; Clinical Trials as Topic ; Databases, Factual ; Drug Industry ; Gene Expression Regulation, Neoplastic ; Genomics ; Humans ; Intellectual Property ; Interprofessional Relations ; Mutation ; Neoplasms/genetics/*therapy ; *Patient Care Management ; Private Sector ; Proteomics ; Public Sector
    Print ISSN: 0036-8075
    Electronic ISSN: 1095-9203
    Topics: Biology , Chemistry and Pharmacology , Computer Science , Medicine , Natural Sciences in General , Physics
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 3
    facet.materialart.
    Unknown
    American Association for the Advancement of Science (AAAS)
    Publication Date: 2013-11-16
    Description: 〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Nijman, Sebastian M B -- Friend, Stephen H -- New York, N.Y. -- Science. 2013 Nov 15;342(6160):809-11. doi: 10.1126/science.1244669.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/24233712" target="_blank"〉PubMed〈/a〉
    Keywords: Animals ; Drosophila melanogaster/genetics ; Gene Targeting ; *Genes, Lethal ; *Genes, Modifier ; Genetic Therapy/*methods ; Humans ; Immunotherapy ; Molecular Targeted Therapy ; Mutation ; Neoplasms/*genetics/*therapy ; Saccharomyces cerevisiae/genetics ; Tumor Suppressor Proteins/genetics
    Print ISSN: 0036-8075
    Electronic ISSN: 1095-9203
    Topics: Biology , Chemistry and Pharmacology , Computer Science , Medicine , Natural Sciences in General , Physics
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 4
    Publication Date: 1997-01-17
    Description: Since 1990, the National Cancer Institute (NCI) has screened more than 60,000 compounds against a panel of 60 human cancer cell lines. The 50-percent growth-inhibitory concentration (GI50) for any single cell line is simply an index of cytotoxicity or cytostasis, but the patterns of 60 such GI50 values encode unexpectedly rich, detailed information on mechanisms of drug action and drug resistance. Each compound's pattern is like a fingerprint, essentially unique among the many billions of distinguishable possibilities. These activity patterns are being used in conjunction with molecular structural features of the tested agents to explore the NCI's database of more than 460,000 compounds, and they are providing insight into potential target molecules and modulators of activity in the 60 cell lines. For example, the information is being used to search for candidate anticancer drugs that are not dependent on intact p53 suppressor gene function for their activity. It remains to be seen how effective this information-intensive strategy will be at generating new clinically active agents.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Weinstein, J N -- Myers, T G -- O'Connor, P M -- Friend, S H -- Fornace, A J Jr -- Kohn, K W -- Fojo, T -- Bates, S E -- Rubinstein, L V -- Anderson, N L -- Buolamwini, J K -- van Osdol, W W -- Monks, A P -- Scudiero, D A -- Sausville, E A -- Zaharevitz, D W -- Bunow, B -- Viswanadhan, V N -- Johnson, G S -- Wittes, R E -- Paull, K D -- New York, N.Y. -- Science. 1997 Jan 17;275(5298):343-9.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Laboratory of Molecular Pharmacology (LMP), Division of Basic Science, National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD 20892, USA. weinstein@dtpax2.ncifcrf.gov〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/8994024" target="_blank"〉PubMed〈/a〉
    Keywords: Algorithms ; Antineoplastic Agents/chemistry/*pharmacology ; Cluster Analysis ; *Computational Biology ; Computer Communication Networks ; *Databases, Factual ; *Drug Screening Assays, Antitumor ; Genes, p53 ; Humans ; Molecular Structure ; Mutation ; Software ; Tumor Cells, Cultured ; Tumor Suppressor Protein p53/physiology
    Print ISSN: 0036-8075
    Electronic ISSN: 1095-9203
    Topics: Biology , Chemistry and Pharmacology , Computer Science , Medicine , Natural Sciences in General , Physics
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 5
    facet.materialart.
    Unknown
    American Association for the Advancement of Science (AAAS)
    Publication Date: 1993-02-12
    Description: 〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Malkin, D -- Friend, S H -- New York, N.Y. -- Science. 1993 Feb 12;259(5097):878.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/8438145" target="_blank"〉PubMed〈/a〉
    Keywords: *Genes, p53 ; Humans ; Li-Fraumeni Syndrome/*genetics ; *Mutation
    Print ISSN: 0036-8075
    Electronic ISSN: 1095-9203
    Topics: Biology , Chemistry and Pharmacology , Computer Science , Medicine , Natural Sciences in General , Physics
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 6
    facet.materialart.
    Unknown
    American Association for the Advancement of Science (AAAS)
    Publication Date: 2014-05-31
    Description: 〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Friend, Stephen H -- Schadt, Eric E -- New York, N.Y. -- Science. 2014 May 30;344(6187):970-2. doi: 10.1126/science.1255648.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Sage Bionetworks, Seattle, WA, 98109 USA Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic Sciences and the Icahn Institute for Genomics and Multiscale Biology, New York, NY 10029, USA. friend@sagebase.org eric.schadt@exchange.mssm.edu. ; Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic Sciences and the Icahn Institute for Genomics and Multiscale Biology, New York, NY 10029, USA. friend@sagebase.org eric.schadt@exchange.mssm.edu.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/24876479" target="_blank"〉PubMed〈/a〉
    Keywords: DNA Mutational Analysis ; *Genetic Association Studies ; Genetic Diseases, Inborn/*genetics/*therapy ; Genetic Predisposition to Disease/*genetics ; Genomics ; *Health ; Humans ; Molecular Targeted Therapy/*trends ; Mutation
    Print ISSN: 0036-8075
    Electronic ISSN: 1095-9203
    Topics: Biology , Chemistry and Pharmacology , Computer Science , Medicine , Natural Sciences in General , Physics
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...